CTA-PB

E. I. du Pont de Nemours and Company (DuPont) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly report (Form 10-Q) for E. I. du Pont de Nemours and Company for the period ended September 30, 2007. DuPont is a large accelerated filer engaged in the manufacture and sale of agricultural products, coatings, electronic materials, performance materials, pharmaceuticals, and safety products. The company operates globally, with significant revenue generated outside the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6% in Q3 2007, driven by a 2% increase in local selling prices, a 2% favorable currency impact, and a 2% volume increase. International sales grew 11%, offsetting a modest decline in U.S. sales due to weak automotive and residential construction demand.
• Profitability: Net income rose 8% year-over-year. The effective tax rate decreased significantly to 16.2% in Q3 2007 compared to 23.7% in 2006, largely due to tax benefits associated with foreign currency hedging policies.
• Cost Structure: Cost of Goods Sold (COGS) increased 7% to $5.1 billion. COGS as a percentage of sales rose to 77% (from 75% in 2006) due to higher raw material, energy, and distribution costs not fully covered by price increases.
• Other Income: Other income, net, increased to $365 million, primarily due to higher Cozaar/Hyzaar royalty income and a $25 million contract termination payment in the Agriculture & Nutrition segment.
• Segment Performance:
  • Agriculture & Nutrition: Sales up 21%; Pretax operating loss narrowed to $96 million from $154 million.
  • Coatings & Color Technologies: Sales up 2%; Pretax operating income decreased to $204 million from $281 million, impacted by higher costs and the absence of a prior-year insurance recovery.
  • Performance Materials: Sales up 6%; Pretax operating income increased 16% to $196 million.

Guidance, Outlook, and Risks

• 2007 Outlook: Management updated full-year 2007 earnings per share guidance to a range of $3.06 to $3.11 (previously about $3.09). This update reflects a $0.09 per share year-to-date charge for litigation liabilities.
• 2008 Outlook: The company expects positive growth for 2008, with earnings per share projected in the range of $3.31 to $3.52. Drivers include strong revenue growth in emerging markets and the Agriculture & Nutrition segment, moderated by potential weakness in U.S. housing/automotive markets and ingredient cost uncertainty.
• Capital Allocation: The company completed its $5 billion share buyback plan (authorized in 2005) by September 30, 2007, retiring 113 million shares. A $2 billion plan from 2001 remains active but had no purchases in Q3 2007. The quarterly dividend was increased to $0.41 per share for Q4 2007.
• Key Risks & Contingencies:
  • PFOA Litigation & Regulation: Significant ongoing exposure related to perfluorooctanoic acid (PFOA) at the Washington Works site. The company has established reserves of approximately $0.7 million for environmental activities and $20 million for health studies and water treatment systems. A class action settlement regarding drinking water exposure is in place, with potential future costs for medical monitoring if a link to disease is proven.
  • Benlate Litigation: Ongoing lawsuits regarding crop damage and birth defects. Reserves of $9 million exist for settlements, with total incurred costs of approximately $2 billion to date.
  • Antitrust Matters: Increased reserves by $65 million for EU antitrust allegations regarding synthetic rubber markets.
  • Environmental Remediation: Total environmental liability reserve is $349 million, with potential liabilities ranging up to two to three times this amount under adverse circumstances.

Investor Verification Checklist

• Verify the sustainability of the 16.2% effective tax rate in Q3 2007, as it was significantly lower than the prior year due to specific hedging tax benefits.
• Monitor the status of the independent science panel regarding PFOA health effects, as a finding of a "probable link" could trigger up to $235 million in medical monitoring costs.
• Assess the impact of rising raw material and energy costs on future margins, given that price increases have not fully offset these costs in recent quarters.
• Review the progress of the Agriculture & Nutrition segment's restructuring and investment plans, which contributed to a narrowing loss but increased fixed costs.
• Confirm the timeline and potential outcomes of the EU antitrust investigation and the Benlate birth defect settlement approval.